Undisclosed IL-13 and OX-40L targetting bispecific antibody / Almirall - LARVOL DELTA

Advancing a broad Medical Dermatology pipeline (Businesswire) - "In 2026, Almirall plans to initiate 3 additional PoC clinical studies with an anti-IL-21 mAb targeting hidradenitis suppurativa and one additional inflammatory skin disease for the anti-IL-1RAP and the IL-2muFc mutant fusion protein, respectively. Furthermore, Almirall plans to advance a bispecific antibody targeting both IL-13 and OX-40L for the treatment of atopic dermatitis into Phase I in the first half of 2026."

New P1 trial • New P3 trial • Atopic Dermatitis • Hidradenitis Suppurativa